Since HDAC inhibitors are already used in cancer therapy and are on trials for other non tumoral/fibrotic diseases, the understanding of the role of HDAC1 in the maintenance of a mesenchymal state in MCs has both a basic and a translational relevance. Here, HDAC1 is linked to cancer.